2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo M, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years. JAMA Dermatology 2024, 161 PMID: 39602111, DOI: 10.1001/jamadermatol.2024.4688.Peer-Reviewed Original ResearchLong-term extension trialsExposure-adjusted incidence ratesSevere plaque psoriasisLong-term extensionModerate to severe plaque psoriasisAdverse eventsPlaque psoriasisDouble-blind phase 3 trialStatic Physician's Global Assessment scoreDiscontinuation due to adverse eventsDay 1Physician Global Assessment scoreIncidence rateEffective long-term treatmentUpper respiratory tract infectionClinical response rateGlobal Assessment scorePhase 3 trialRespiratory tract infectionsWeeks of treatmentYear of treatmentLong-term treatmentAdverse cardiovascular eventsLong-term safetyCumulative period503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice
Wang Z, Martins B, Ardeleanu M, Yang M, Bégo-Le-Bagousse G, Sierka D, Strober B. 503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice. British Journal Of Dermatology 2024, 190: ii9-ii9. DOI: 10.1093/bjd/ljad498.011.Peer-Reviewed Original ResearchHealth statusIndividual patient levelTreatment satisfactionAtopic Dermatitis Control ToolPatient levelQuality of life of childrenObservational study of adultsAtopic dermatitisLongitudinal cohort studyPatient-reported outcomesPatient support programStudy of adultsQuality of lifeDupilumab treatmentMonth 1Lives of childrenBaseline surveyChronic inflammatory skin diseasePatients maintained responseSupport programsModerate-to-severe ADCohort studyLong-term treatmentInflammatory skin diseaseOutcome trajectories
2023
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
Kimball A, Delevry D, Yang M, Chuang C, Wang Z, Bégo-Le-Bagousse G, Martins B, Wu E, Shumel B, Wang J, Sierka D, Chao J, Strober B. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study. Dermatology And Therapy 2023, 13: 2107-2120. PMID: 37552431, PMCID: PMC10442302, DOI: 10.1007/s13555-023-00965-5.Peer-Reviewed Original ResearchPatient-reported outcomesAtopic Dermatitis Control ToolAD therapyDermatology Life Quality IndexActivity Impairment QuestionnaireLong-term therapyLife Quality IndexLong-term treatmentPatient-reported benefitsPatient support programClinical practice settingReal-world studyAdequate disease controlLong-term effectivenessDupilumab useImpairment QuestionnaireSevere ADAD medicationsAtopic dermatitisTherapy useSkin symptomsCurrent therapiesSleep problemsDupilumabPractice settingsBimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
Strober B, Tada Y, Mrowietz U, Lebwohl M, Foley P, Langley R, Warren R, Wang M, Vanvoorden V, Szilagyi B, Ciaravino V, Paul C. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. British Journal Of Dermatology 2023, 188: 749-759. PMID: 36967713, DOI: 10.1093/bjd/ljad035.Peer-Reviewed Original ResearchConceptsOngoing open-label extensionSevere plaque psoriasisBody surface areaDermatology Life Quality IndexWeek 16Plaque psoriasisNonresponder imputationPASI 100Investigator's Global Assessment 0/1Open-label extension trialDLQI 0/1 responsePASI 90 respondersOpen-label extensionHealth-related qualityLong-term efficacyLife Quality IndexLong-term treatmentLoss of responseYear 3Absolute PASIPASI 90Efficacy outcomesClinical responsePsoriasis AreaExtension trial